Alteon: foundation grant to fund phase 2 study of alagebrium on renal function in type 1 diabetes

By Lisa Kerner

Charlotte, N.C., July 10 - Alteon Inc. said a grant from the from the Juvenile Diabetes Research Foundation will help fund a multinational phase 2 clinical study of the effect of the company's lead compound alagebrium on renal function in patients with type 1 diabetes and microalbuminuria.

The randomized, double-blind, placebo-controlled study will include 80 patients with type 1 diabetes between the ages of 18 and 65 in the early stages of kidney disease.

Changes in albumin excretion rate will be the primary endpoint of the study.

"In preclinical studies, we have shown that renal damage in diabetes is partly caused by sugar-protein complexes called Advanced Glycation End-products [AGEs], and that treatment with alagebrium, an AGE Crosslink Breaker, can improve renal function and structure," Alteon collaborator Mark Cooper said in a company news release.

Alteon is a product-based biopharmaceutical company engaged in the development of small molecule drugs to treat and prevent cardiovascular disease and diabetes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.